Skip to main content

Spaventa Andrew's Form 4 filing

Singular Genomics Systems, Inc.OMIC · filed Dec 17, 2024

Accession no.
0000950170-24-137425
Filed
Dec 17, 2024
Trade date
Dec 15-16, 2024
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $3.63K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Spaventa AndrewCIK 0001859701Director, Officer (Chief Executive Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 15, 2024Common StockMOption exerciseAcquired+486–F1–811Direct
Dec 16, 2024Common StockSSaleDisposed−180$20.16F3−$3,628.8631Direct
Dec 16, 2024Common StockGGiftDisposed−306$0.00$0325Direct
Dec 16, 2024Common StockGGiftAcquired+306$0.00$0141,793Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Dec 15, 2024Common StockMOption exerciseDisposed−486$0.00$04,374Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Represents shares of Common Stock issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

Referenced by the price of 1 transaction in Table I.

F3

Weighted average price. These shares were sold in multiple transactions at prices ranging from $20.07 to $20.34 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)